Temsirolimus

Thông số

162635-04-3Số CAS

686-177-0Số EC

[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-meTên IUPAC

C56H87NO16Công thức hóa học

1030.3 g/molKhối lượng phân tử

Temsirolimus; CCI-779; Torisel; 162635-04-3; 624KN6GM2T; DTXSID2040945; DTXCID0020945; Rapamycin 42-(2,2-bis(hydroxymethyl)propionate); Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate); temsirolimusum; Temsirolimus Injection; RefChem:56883; L01XE09; ((1R,2R,4S)-4-((2R)-2-((1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraen-12-yl)propyl)-2-methoxycyclohexyl) 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; MFCD00934421; CHEMBL1201182; NCGC00167518-01; Temsirolimus (>80%); Cci 779; C56H87NO16; Temserolimus; Temsirolimus?; NSC-683864; Temsirolimus (CCI-779, NSC 683864); Temsirolimus [USAN]; TEMSIROLIMUS [MI]; TEMSIROLIMUS [INN]; TEMSIROLIMUS [JAN]; TEMSIROLIMUS [VANDF]; UNII-624KN6GM2T; TEMSIROLIMUS [MART.]; 40-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin; TEMSIROLIMUS [WHO-DD]; WAY-CCI 779; GTPL5892; orb1226033; orb1306354; TEMSIROLIMUS [EMA EPAR]; HSDB 7931; Temsirolimus, >=98% (HPLC); CBPNZQVSJQDFBE-FUXHJELOSA-N; GLXC-90175; TEMSIROLIMUS [ORANGE BOOK]; [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]; Temsirolimus [USAN:INN:BAN:JAN]; Tox21_112515; BDBM50343413; s1044; AKOS025142069; CCG-264790; CS-0129; FR61494; SDCCGSBI-0654330.P001; NCGC00167518-02; NCGC00167518-04; NCGC00167518-05; NCGC00167518-09; HY-50910; CAS-162635-04-3; AB01274736-01; AB01274736_02; SR-01000898799; Q7699074; SR-01000898799-3; BRD-K08177763-001-02-6; Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate; [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxy-cyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methyl-propanoate; [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoateEETên gọi khác